SCHEMBL4476973

SCHEMBL4476973

Cn1cnc(-c2cccc(NC(=O)Cc3ccccc3Cl)c2)c1-c1cc2c(N)ncnc2s1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TEK Q02763 6/20 0.73
FLT1 P17948 3/20 0.60
KDR P35968 3/20 0.60
KCNJ5 P48544 4/20 0.42
KCNJ3 P48549 4/20 0.42
KCNJ6 P48051 2/20 0.41
MAP4K4 O95819 5/20 0.40
SRC P12931 2/20 0.39
NR1I2 O75469 1/20 0.38
PLK4 O00444 1/20 0.38
AURKA O14965 1/20 0.38
DYRK3 O43781 1/20 0.38
PRKD3 O94806 1/20 0.38
LCK P06239 1/20 0.38
FYN P06241 1/20 0.38
FES P07332 1/20 0.38
CSF1R P07333 1/20 0.38
LYN P07948 1/20 0.38
FGFR1 P11362 1/20 0.38
AXL P30530 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4471484 0.91 TEK (0.73) TEKFLT1KDRMAP4K4SRC
SCHEMBL4485440 0.88 TEK (0.70) TEKFLT1KDRMAP4K4SRC
SCHEMBL4484707 0.86 TEK (0.83) TEKFLT1KDRAURKAFLT3
SCHEMBL4464925 0.85 TEK (0.70) TEKFLT1KDRMAP4K4SRC
SCHEMBL4796059 0.84 TEK (1.00) TEKFLT1KDRMAP4K4SRC
SCHEMBL4802186 0.84 TEK (0.86) TEKFLT1KDRMAP4K4FLT4
SCHEMBL4471994 0.84 TEK (0.85) TEKFLT1KDRFLT4FLT3
SCHEMBL4801489 0.83 TEK (0.83) TEKFLT1KDRLIMK1BRAF
SCHEMBL4770479 0.82 TEK (0.51) TEKKDRKCNJ5KCNJ3KCNJ6
SCHEMBL4480247 0.81 TEK (0.85) TEKFLT1KDRMAP4K4LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7476677-B2 Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2 ASTRAZENECA AB (SE) 2009-01-13 US claimed
EP-1716155-B1 SUBSTITUTED THIENO- AND THIAZOLO[2,3-D]PYRIMIDINES AND [2,3-C]PYRIDINES AS INHIBITORS OF TIE2 ASTRAZENECA AB (SE) 2008-02-27 EP claimed
US-20070135455-A1 Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 ASTRA ZENECA AB (SE) 2007-06-14 US claimed
US-7476677-B2 Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2 ASTRAZENECA AB (SE) 2009-01-13 US disclosed
US-20070135455-A1 Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 ASTRA ZENECA AB (SE) 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135455-A1 Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of tie2 TIE1, TEK, TEKT1 TEK 2/4885FLT1 6/4885KDR 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.